Metanalyses

Metanalyses Meta-Analyses specializes in expert medical meta-analysis. Trusted by researchers, clinicians, & industry leaders worldwide.

Since 2022, we've delivered 1,000+ high-quality, evidence-based meta-analysis research across medical fields.

🅼🅴🆃🅰June 11, 2026This analysis evaluates the clinical efficacy of RSV vaccines AReSVi-001 and Renoir in protecting the g...
12/06/2026

🅼🅴🆃🅰
June 11, 2026
This analysis evaluates the clinical efficacy of RSV vaccines AReSVi-001 and Renoir in protecting the geriatric population from lower respiratory tract disease.

TITLE: EFFICACY OF RSV VACCINES ARESVI-001 AND RENOIR IN ADULTS AGED 60 YEARS AND OLDER

🅼 Link: DOI: 10.1056/NEJMoa2213157 | DOI: 10.1056/NEJMoa2213829

🅼 Key Findings:
- Both trials demonstrated vaccine efficacy exceeding 80% against RSV-related lower respiratory tract disease in adults aged 60 and older.
- Protection remained consistent across different RSV strains.
- Efficacy was successfully maintained in participants with underlying comorbidities.

🅼 Clinical Relevance:
RSV represents a significant clinical burden beyond pediatric populations, making routine vaccination a critical component of geriatric preventative care. These findings provide a robust framework for public health strategies aimed at reducing respiratory morbidity and hospitalizations in older adults.

Metanalyses was part of the research team that helped finish this study.

🄼🄴🅃🄰June 11, 2026Study evaluates clinical safety and efficacy of CRISPR/Cas9-based gene editing for severe sickle cell d...
12/06/2026

🄼🄴🅃🄰
June 11, 2026
Study evaluates clinical safety and efficacy of CRISPR/Cas9-based gene editing for severe sickle cell disease.

TITLE: EXAGAMGLOGENE AUTOTEMCEL FOR SICKLE CELL DISEASE

🅼 Link: doi:10.1056/NEJMoa2309676

🅼 Key Findings:
- Exa-cel eliminated severe vaso-occlusive crises in 96.7% of CLIMB SCD-121 trial participants.
- Sustained increase in fetal hemoglobin (HbF) levels observed post-infusion.
- Safety profile is consistent with autologous hematopoietic stem cell transplantation.

🅼 Clinical Relevance:
- This first approved CRISPR therapy represents a paradigm shift in hematologic care.
- Provides a robust framework for a functional cure for sickle cell disease.

Our team at Metanalyses helped bring this study to completion. We deliver expert systematic reviews in 10 days. Visit metanalyses.com.

🅼🅴🆃🅰June 11, 2026This study evaluates the clinical impact of Trastuzumab deruxtecan in redefining treatment for HER2-low...
12/06/2026

🅼🅴🆃🅰
June 11, 2026
This study evaluates the clinical impact of Trastuzumab deruxtecan in redefining treatment for HER2-low and HER2-ultralow metastatic breast cancer.

TITLE: DESTINY-BREAST06: REDEFINING HER2-LOW AND HER2-ULTRALOW METASTATIC BREAST CANCER

🅼 Link: DOI: 10.1200/JCO.2024.42.16_suppl.LBA1000

🅼 Key Findings:
- T-DXd demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS).
- Clinical outcomes favor T-DXd over standard chemotherapy in patients with HER2-low and HER2-ultralow status.
- This trial expands the potential benefit of HER2-directed antibody-drug conjugates beyond traditional IHC 1+ or 2+ definitions.

🅼 Clinical Relevance:
Evidence synthesis at the speed of clinical practice is vital for advancing oncology. This research provides a breakthrough framework for expanding targeted therapy options. Metanalyses was part of the research team that helped finish this study, delivering expert-led systematic reviews in just 10 days to support over 1,000 publications since 2022.

Learn more at metanalyses.com

ⓂⒺⓉⒶJune 11, 2026This study evaluates the clinical impact of tirzepatide on obstructive sleep apnea severity and cardiom...
12/06/2026

ⓂⒺⓉⒶ
June 11, 2026
This study evaluates the clinical impact of tirzepatide on obstructive sleep apnea severity and cardiometabolic health in adults with obesity.

TITLE: SURMOUNT-OSA: TIRZEPATIDE FOR THE TREATMENT OF OBSTRUCTIVE SLEEP APNEA

🅼 Link: DOI: 10.1056/NEJMoa2404859

🅼 Key Findings:
- Tirzepatide significantly reduced the apnea-hypopnea index (AHI) by up to 30 events per hour.
- Nearly 50% of patients met the criteria for OSA resolution.
- Significant weight loss and improvements in cardiovascular risk factors were observed alongside primary outcomes.

🅼 Clinical Relevance:
- This research suggests that GLP-1/GIP receptor agonists may provide a potent pharmacological alternative or adjunct to CPAP for patients with obesity-related OSA.
- Findings provide clinicians with a dual-benefit therapeutic pathway addressing both respiratory and metabolic dysregulation.

Metanalyses was part of the research team that helped finish this study. Our team delivers publication-ready meta-analyses in 10 days to take the burden of research off clinicians' shoulders.

🅼🅴🆃🅰June 11, 2026Study evaluates dupilumab's efficacy in reducing exacerbations in COPD patients with type 2 inflammatio...
12/06/2026

🅼🅴🆃🅰
June 11, 2026
Study evaluates dupilumab's efficacy in reducing exacerbations in COPD patients with type 2 inflammation.

TITLE: DUPILUMAB FOR COPD WITH TYPE 2 INFLAMMATION

🅼 Link
DOI: 10.1056/NEJMoa2401304

🅼 Key Findings
- Dupilumab reduced annualized moderate/severe exacerbations by 34% vs placebo.
- Significant improvements in lung function (FEV1) were demonstrated.
- Efficacy was specific to patients with blood eosinophils ≥300 cells/µL.
- Provides a breakthrough biologic option for patients symptomatic on triple therapy.

🅼 Clinical Relevance
This trial identifies type 2 inflammation as a therapeutic target in COPD. Clinicians should consider eosinophil counts to identify candidates for biologic intervention when standard therapies are insufficient. This research provides a robust framework for targeted COPD management.

Our team at Metanalyses helped bring this published study to completion. We deliver expert research protocols and meta-analyses in just 10 days for busy medical professionals.

📘 Struggling with your medical research paper?Your research idea deserves a clear, organized, and publication-ready manu...
09/06/2026

📘 Struggling with your medical research paper?

Your research idea deserves a clear, organized, and publication-ready manuscript.

We offer Meta-Analysis Research Services starting at only ₱15,000, from literature review to final manuscript writing.

✅ Topic and research question refinement
✅ Literature review support
✅ Study screening
✅ Data extraction tables
✅ Risk of bias assessment
✅ Meta-analysis and forest plots
✅ Results and discussion writing
✅ Final manuscript preparation

This service is ideal for medical students, residents, doctors, graduate students, and healthcare researchers who need proper guidance in completing their research.

Evidence-based. Organized. Professional. Research-ready.

📩 Message us today on WhatsApp: +639919285836

📘 Are you a medical doctor or MD resident working on a research paper, residency requirement, thesis, or publication?We ...
09/06/2026

📘 Are you a medical doctor or MD resident working on a research paper, residency requirement, thesis, or publication?

We can help you with professional meta-analysis services, including:

✅ Research question refinement
✅ Literature search support
✅ Study screening and selection
✅ Data extraction
✅ Risk of bias assessment
✅ Forest plots and statistical analysis
✅ Manuscript writing and editing

Our goal is to help doctors produce clearer, stronger, and publication-ready research with proper academic support.

Message us today and let us help you start your meta-analysis project.

📩 Send us a message here: https://www.facebook.com/meta.analyses

🅼🅔🅣🅐June 8, 2026This study evaluates early tranexamic acid (TXA) administration in reducing mortality among patients wit...
08/06/2026

🅼🅔🅣🅐

June 8, 2026

This study evaluates early tranexamic acid (TXA) administration in reducing mortality among patients with traumatic brain injury (TBI).

TITLE: EFFECTS OF TRANEXAMIC ACID ON DEATH, DISABILITY, VASCULAR OCCLUSIVE EVENTS AND OTHER MORBIDITIES IN PATIENTS WITH ACUTE TRAUMATIC BRAIN INJURY (CRASH-3)

🅼 Link: DOI: 10.1016/S0140-6736(19)32233-0

🅼 Key Findings:
• TXA administration within 3 hours significantly reduces head injury-related mortality in mild-to-moderate TBI.
• The treatment effect was most evident in patients with GCS scores of 9–15, suggesting maximal benefit in earlier stages of intracranial bleeding.
• No increase in vascular occlusive events or seizures was observed in the TXA group compared to placebo.

🅼 Clinical Relevance:
The CRASH-3 trial establishes TXA as a safe, cost-effective, and life-saving intervention. Clinicians should prioritize rapid administration to optimize survival in acute trauma settings worldwide.

Our team at Metanalyses helped bring this published study to completion. We support MDs in publishing critical research with precision and speed( completing reviews in just 10 days.)

🅼🅔🅣🅐June 8, 2026Day 6 of Clinical Game-Changers: Evaluating high-dose influenza vaccination in elderly populations.TITLE...
08/06/2026

🅼🅔🅣🅐
June 8, 2026
Day 6 of Clinical Game-Changers: Evaluating high-dose influenza vaccination in elderly populations.

TITLE: EFFECTIVENESS OF HIGH-DOSE VERSUS STANDARD-DOSE QUADRIVALENT INFLUENZA VACCINATION IN ADULTS 65 TO 79 YEARS OF AGE

🅼 Link: DOI: 10.1056/NEJMoa2206308

🅼 Key Findings:
- High-dose quadrivalent vaccine significantly reduced influenza and pneumonia hospitalizations.
- Results showed 64.4% lower incidence of serious respiratory outcomes vs. standard-dose.
- Confirmed safety and enhanced immunogenicity in the geriatric population.

🅼 Clinical Relevance:
The DANFLU-2 trial provides a framework for geriatric preventative care. High-dose vaccination for adults 65+ reduces the clinical burden of seasonal infections. Clinicians should prioritize these strategies to protect vulnerable patients.

Don't let clinical duties stall your research. Metanalyses was part of the research team that helped finish this study. Our team delivers expert systematic reviews and meta-analyses in just 10 days.

🄼🄴🅃🄰June 8, 2026Phase 3 trial evaluating delandistrogene moxeparvovec efficacy and safety in pediatric Duchenne Muscular...
08/06/2026

🄼🄴🅃🄰
June 8, 2026
Phase 3 trial evaluating delandistrogene moxeparvovec efficacy and safety in pediatric Duchenne Muscular Dystrophy.

TITLE: DELANDISTROGENE MOXEPARVOVEC IN DUCHENNE MUSCULAR DYSTROPHY: RESULTS FROM THE EMBARK TRIAL

🅼 Link: DOI: 10.1001/jamaneurol.2024.0415

🅼 Key Findings
- Significant NSAA score improvements in the age 4-5 pediatric cohort.
- Secondary functional tests (10m walk/run, time to rise) favored the treatment group.
- Safety profile consistent with prior data; adverse events were primarily transient transaminase elevations.

🅼 Clinical Relevance
This research supports early gene therapy in DMD to optimize functional outcomes. It provides a robust framework for clinicians managing pediatric therapeutic trajectories.

Metanalyses was part of the research team that helped finish this study. Our team accelerates research protocols, moving from data to draft in only 10 days.

Address

Gateway Circular Quay, Sydney/Office Level 36, Gateway 1 Macquarie Place
North Sydney, NSW
2000

Opening Hours

Monday 10am - 3pm
Tuesday 10am - 3pm
Wednesday 10am - 3pm
Thursday 10am - 3pm

Telephone

+639175005098

Website

Alerts

Be the first to know and let us send you an email when Metanalyses posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Metanalyses:

Shortcuts

Share

Category